WuXi STA expands into Europe

China-based pharmaceutical CDMO WuXi STA has completed the acquisition of a drug product manufacturing facility in Couvet, Switzerland, from Bristol-Myers Squibb, as announced earlier in the year. The site is WuXi STA’s first in Europe. It makes tablets and capsules.

Through this transaction, WuXi STA has increased its global presence to eight R&D and manufacturing sites across Asia, North America and Europe, including a pharmaceutical clinical and commercial manufacturing complex on a 78-hectare campus at Middletown, Delaware, that was announced in early July.

This will feature space for testing laboratories, API manufacture and the manufacture and packaging of solid dosage pharmaceutical products and sterile products. Due open in 2024, it should bring 500 full-time jobs by 2026, with the potential to grow to 1,000 in time.